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of chronic kidney disease. Increased albumin in urine leads
to apoptosis and ﬁbrosis of podocytes and tubular cells and
is a major cause of functional deterioration. There have been
many attempts to target ﬁbrosis, but because of the lack of
appropriate agents, few have targeted apoptosis. Our group
has described an ouabain-activated Na,K-ATPase/IP3R
signalosome, which protects from apoptosis. Here we show
that albumin uptake in primary rat renal epithelial cells is
accompanied by a time- and dose-dependent mitochondrial
accumulation of the apoptotic factor Bax, down-regulation
of the antiapoptotic factor Bcl-xL and mitochondrial
membrane depolarization. Ouabain opposes these effects
and protects from apoptosis in albumin-exposed proximal
tubule cells and podocytes. The efﬁcacy of ouabain as an
antiapoptotic and kidney-protective therapeutic tool was
then tested in rats with passive Heymann nephritis, a model
of proteinuric chronic kidney disease. Chronic ouabain
treatment preserved renal function, protected from renal
cortical apoptosis, up-regulated Bax, down-regulated Bcl-xL,
and rescued from glomerular tubular disconnection and
podocyte loss. Thus we have identiﬁed a novel clinically
feasible therapeutic tool, which has the potential to protect
from apoptosis and rescue from loss of functional tissue in
chronic proteinuric kidney disease.
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Kidney International (2016) 90, 135–148C hronic kidney disease (CKD) is a rapidly increasingworld-wide public health problem.1 CKD results frommany causes, including diabetes, glomerulonephritis,
hypoxia, hypertension, infections, and polycystic kidney dis-
ease. Most forms of CKD are progressive1–3 and characterized
by disrupted glomerular perm-selectivity, albuminuria, loss of
podocytes, interstitial ﬁbrosis, and glomerular-tubular
disconnection.4–9 Albuminuria, a well-documented predictor
of progressive loss of kidney function, is considered a cause of
kidney damage and loss of function.10–13 The nature of
albumin toxicity has been extensively studied in the past
decade, and it is well recognized that prolonged exposure of
renal tubular cells to albumin results in apoptosis and
ﬁbrosis,14–18 but their interrelationship is not yet fully under-
stood. There are several ongoing trials aimed at halting pro-
gression of CKD using drugs targeted to inhibit proﬁbrotic
and/or stimulate antiﬁbrotic molecular pathways,19–22 but
there are few attempts to target the apoptotic process, mainly
because of lack of nontoxic agents.
Apoptosis is triggered either via an extrinsic pathway
stimulated by activation of plasma membrane death receptors
or via an intrinsic mitochondrial pathway. The intrinsic
apoptotic pathway is controlled by the family of B-cell lym-
phoma (Bcl)-2 proteins. The mitochondrial apoptotic
pathway is initiated by activation of Bax, a prominent pro-
apoptotic member of the Bcl-2 family, to the outer mito-
chondrial membrane, where it oligomerizes and penetrates
the inner mitochondrial membrane. This results in release of
cytochrome C and caspase activation, the apoptotic executors.
B-cell lymphoma–extra large (Bcl-xL), a prominent anti-
apoptotic member of the Bcl-2 family, counteracts Bax
accumulation on the mitochondria and Bax-induced per-
meabilization of the mitochondrial membranes.23,24
Our group has identiﬁed an antiapoptotic signal activated
by the cardiotonic steroid ouabain, which involves interac-
tion between sodium-potassium adenosine triphosphatase
(Na,K-ATPase) and the inositol 1,4,5-triphosphate receptor
(IP3R) and triggering of slow intracellular calcium oscilla-
tions. We have shown that the ouabain signal may interfere
with the apoptotic process by down-regulation of the
apoptotic factor Bax and up-regulation of the antiapoptotic
factor Bcl-xL.25–30 Studies from us and other investigators135
bas i c re sea r ch I Burlaka et al.: Apoptosis inhibition rescues from albumin toxicityhave provided evidence for a tissue protective effect of
ouabain.30–36
The aim of this study has been to test the hypothesis that
activation of the ouabain signal can, via down-regulation of
Bax and up-regulation of Bcl-xL, rescue from the onset of
albumin-triggered apoptotic process and thereby halt the
progression of CKD. If this would be the case, ouabain may be
a good candidate for a clinically feasible antiapoptotic drug.
Proximal tubular cells (PTCs) are the main target for the toxic
effects of albumin overload,17 and loss of early PTCs will
result in glomerular-tubular disconnection and irreversible
renal damage.5,7
To assess at which stage ouabain interferes with the
apoptotic process, Bax recruitment to the mitochondria,
changes of the mitochondrial membrane potential, and
cellular abundance and localization of Bcl-xL were sequen-
tially studied in a homogenous preparation of primary rat
PTCs (RPTCs). Podocytes, which constitute a well-recognized
locus minoris resistentiae in CKD,37,38 were also examined
with regard to their apoptotic response to albumin and the
rescuing effect of ouabain. To obtain the ﬁrst proof of
principle that ouabain may protect from apoptosis and pro-
gressive renal damage in proteinuric CKD, we used a well-
established rat model of human proteinuric kidney disease,
passive Heymann nephritis (PHN).39,40
RESULTS
Albumin uptake into primary renal cells triggers apoptosis
followed by increased expression of TGF-b 1: protective effect
of ouabain
It is well documented that excessive uptake of albumin into
RPTCs triggers apoptosis30,41–43 and generation of proﬁbrotic
factors, such as transforming growth factor (TGF)-b.44 To
determine the order by which these processes are initiated, we
incubated RPTCs with fatty acid and endotoxin-free albumin
(10 mg/ml) for 2, 4, 8, and 18 hours. The level of apoptosis
triggered by albumin was determined with terminal deoxy-
nucleotidyltransferase–mediated dUTP nick end-labeling
(TUNEL) staining45 and expression of the proﬁbrotic TGF-b1
precursor with immunoblotting (Figure 1a–d). Apoptotic
index (AI) was signiﬁcantly increased after 2 hours of
albumin incubation and continued to increase during the
following 16 hours. In contrast, expression of the TGF-b1
precursor was not increased until after 8 hours of albumin
incubation.
The apoptotic effect of albumin was dose-dependent and
coincubation with ouabain (5 nM) resulted in a robust
reduction of AI with all tested albumin concentrations (5, 10,
or 20 mg/ml for 8 or 18 hours) (Figure 1e and f). The
expression of TGF-b precursor in RPTCs exposed to albumin
for 8 or 18 hours was also attenuated by ouabain (5 nM)
(Supplementary Figure S1B). Ouabain did not interfere with
albumin uptake in RPTCs (Supplementary Figure S1C).
To test whether albumin might trigger apoptosis of primary
rat podocytes, isolated glomeruli were plated, cultured for 3
days, and stained with the podocyte-speciﬁc transcriptional136factor WT1.46 AI was determined in cells that had migrated
out from the glomerulus and were WT1-positive (Figure 1g).
Incubation with albumin for 18 hours triggered apoptosis in a
dose-dependent manner. Coincubation with ouabain resulted
in signiﬁcant reduction of AI (Figure 1h).
Ouabain interferes with the albumin triggered intrinsic
apoptotic pathway
In RPTCs exposed to albumin (10 mg/ml) for 8 hours, Bcl-xL
abundance was decreased and the Bax abundance was
increased as measured by immunoblotting (Figure 2b and c).
The abundance of cleaved caspase-3 was increased, indicating
that the apoptotic process was reaching the point of no
return. Ouabain (5 nM) partially rescued from Bcl-xL down-
regulation, Bax up-regulation, and increase of cleaved
caspase-3.
The ouabain signaling pathway includes activation of the
IP3R, release of calcium from endoplasmic reticulum via the
IP3R and activation of the prosurvival nuclear factor kB
(nuclear factor kappa-light-chain-enhancer of activated B
cells) p65 subunit (Figure 2a).25,27,47 When cells coincubated
with albumin and ouabain were depleted of calcium from
endoplasmic reticulum stores by sarco/endoplasmic reticu-
lum Ca2þATPase pump inhibition with cyclopiazonic acid
or coincubated with helenalin, a speciﬁc nuclear factor kB
p65 subunit inhibitor, the rescuing effects of ouabain were
abolished (Figure 2b and c). Ouabain had little effect on Bax
and Bcl-xL expression in control cells. The extrinsic
apoptotic pathway can be triggered by incubation with
lipopolysaccharide. Ouabain (5 nM) did not protect against
lipopolysaccharide-triggered cytokine release (Figure 2d,
Supplementary Figure S2).
Ouabain protects from albumin-triggered mitochondrial
dysfunction
To further characterize the involvement of mitochondria in
albumin toxicity, time-sequence studies were performed with
regard to mitochondrial membrane potential, Bax colocali-
zation with mitochondria and Bcl-xL abundance (Figure 3a–c).
Albumin (2.5 mg/ml) caused time-dependent depolarization
of the mitochondrial membrane (Figure 3g). Colocalization
between Bax and mitochondria in albumin-exposed cells
increased in a time-dependent manner and the increase was
signiﬁcant after 2 hours (Figure 3g). The intensity of the
ﬂuorescent signal from Bcl-xL in albumin-incubated RPTCs
decreased in a time-dependent manner. Changes were signiﬁ-
cant after 2 hours of incubation with albumin (Figure 3g).
Albumin had no effect on colocalization between Bcl-xL and
mitochondria (Supplementary Figure S3A). In RPTCs coin-
cubated with albumin (2.5 mg/ml) and ouabain (5 nM) for 8
hours, the effects on mitochondrial accumulation of Bax,
mitochondrial membrane potential, and Bcl-xL abundance
were greatly attenuated (Figure 3d–f). Incubation of RPTCs
with 10 mg/ml albumin resulted in a more pronounced effect
(Supplementary Figure S3B–E) and was seen after 30 minutes
(Supplementary Figure S4A–C).Kidney International (2016) 90, 135–148
Figure 1 | Albumin uptake into primary renal cells triggers apoptosis followed by increased expression of TGF-b1: protective effect of
ouabain. (a) Albumin-induced apoptosis in RPTCs incubated with 10 mg/ml albumin for 2, 4, or 8 hours and vehicle control. RPTCs were TUNEL-
stained (red) to detect apoptotic cells and counterstained with DAPI (blue). Bar ¼ 40 mm for all images. (b) Quantiﬁcation of albumin-induced
apoptosis in RPTCs treated with 10 mg/ml albumin (open bars) or vehicle (gray bars) for 2, 4, 8, or 18 hours. Histograms show mean  SEM.
Experiments were repeated 4 times. The apoptotic index in vehicle-treated (control) cells was stable at 2% for the duration of the 18 hours. The
apoptotic index for 10 mg/ml albumin was signiﬁcantly increased versus control *P < 0.001; #P < 0.01. (c) Albumin-induced TGF-b1 expression
in RPTCs detected by immunoblot. RPTCs were incubated with 10 mg/ml albumin in serum-free medium for 2, 4, or 8 hours. (d) Quantiﬁcation
of albumin-induced TGF-b1 expression in RPTCs incubated with 10 mg/ml albumin (open bars) or vehicle (gray bars) for 2, 4, 8, or 18 hours.
Experiments were repeated 4 times and vehicle control for each time point was set to 100%. Histograms show mean  SEM. *P < 0.001 versus
control. (e,f) Dose dependence of albumin-induced apoptosis in RPTCs. RPTCs were incubated with 0 (vehicle control); 5, 10, or 20 mg/ml
albumin alone (solid line); and in combination with 5 nM ouabain (dashed line) for 8 hours in e or 18 hours in f. Plots represent mean  SEM.
Experiments were repeated 4 times. P < 0.001 for 5, 10, and 20 mg/ml albumin versus vehicle control (0 mg/ml), at both 8 and 18 hours.
P < 0.01 for 5 nM ouabain with 5, 10, and 20 mg/ml albumin versus the corresponding albumin treatment alone, at both 8 and 18 hours.
(g) Primary culture of podocytes; images show isolated rat glomeruli plated and cultured for 3 days. Staining with the podocyte-speciﬁc
transcriptional factor WT1 shown in green and DAPI-stained nuclei shown in blue. Podocytes that migrate out from the glomerulus were used
for the apoptosis study shown in h. Note that a subset of cells (indicated by arrow) are not WT1-positive and therefore are not included in the
analysis. Bars ¼ 20 mm. (h) Dose dependence of albumin-induced apoptosis in podocytes. Podocytes were incubated with 0 (vehicle control);
1, 5, or 10 mg/ml albumin alone (solid line); and in combination with 5 nM ouabain (dashed line) for 18 hours. Only cells positive for the
podocyte marker WT1 were included in the analysis. Plots represent mean  SEM. Experiments were repeated 4 times. P < 0.001 for 5 and
10 mg/ml albumin versus vehicle control (0 mg/ml); P < 0.01 for ouabain treatment together with 5 and 10 mg/ml albumin versus the
corresponding albumin treatment alone. DAPI, 40,6-diamidino-2-phenylindole; RPTCs, rat proximal tubular cells; TGF, transforming growth
factor; TUNEL, terminal deoxynucleotidyltransferase–mediated dUTP nick end-labeling.
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Figure 2 | Ouabain intervenes with the intrinsic apoptotic pathway triggered by albumin, but not with LPS-stimulated cytokine
expression. (a) Cartoon illustrating the ouabain/Na,K-ATPase/IP3R signaling pathway. Ouabain binds to Na,K-ATPase, which triggers interaction
between the Na,K-ATPase and the IP3R through the amino acid residues LKK in the N-terminus of the catalytic a subunit of the Na,K-ATPase.
The interaction activates the IP3R, causing calcium to release from the ER. The slow calcium oscillations promote activation the NF-kB p65
subunit, which leads to protection from apoptosis through stimulation of the antiapoptotic protein Bcl-xL. (b) Western blot showing expression
of Bax, Bcl-xL, caspase-3, and cleaved caspase-3 in RPTCs after 8 hours incubation with 10 mg/ml albumin, 5 nM ouabain, 1 mM Helenalin, and
1mM CPA as indicated. (c) Densitometric quantiﬁcation of Bcl-xL (left), Bax (center), and cleaved caspase-3 (right) after 8 hours incubation with
10 mg/ml albumin, 5 nM ouabain, 1 mM Helenalin, and 1mM CPA as indicated. The density of the band from control cells was set to 100%.
Histograms show the mean  SEM. Experiments were repeated 5 times. *P < 0.001; #P < 0.01. (d) Expression of the inﬂammatory cytokines,
IL-1b and IL-6, after incubation with LPS 1 mg/ml for 0, 1, 2, 4, or 8 hours, and for 8 hours together with 5 nM ouabain as indicated. Bcl-xL, B-cell
lymphoma–extra large; CPA, cyclopiazonic acid; ER, endoplasmic reticulum; IL, interleukin; IP3R, inositol 1,4,5-triphosphate receptor; LPS,
lipopolysaccharide; LKK, Leu-Lys-Lys, critical amino acids for NKA and IP3R interaction; NF, nuclear factor; NKA, sodium-potassium adenosine
triphosphatase, or Na,K-ATPase; RPTCs, rat proximal tubular cells.
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those reported in primary ﬁltrate in proteinuric disease48 can
cause mitochondrial dysfunction, cells were incubated with
0.2 mg/ml albumin. Signiﬁcant reduction of mitochondrial
membrane potential was observed at both 8 and 18 hours. In
cells coincubated with ouabain (5 nM) the mitochondrial
membrane potential was maintained at control levels
(Figure 3h and i).
Chronic ouabain treatment protects from apoptosis in rats
with PHN
To assess the nephroprotective effect of ouabain in vivo, rats
were induced with PHN, a well-studied model of chronic
proteinuric kidney disease with a relatively slow progressive138course.39,40 PHN rats were treated with ouabain (15 mg/kg/day)
or vehicle and followed for 4 months. Control rats were treated
with vehicle. Treatment with this concentration of ouabain
does not affect heart rate and arterial pressure (Supplementary
Figure S5A). Signiﬁcant albuminuria was present 2 weeks after
PHN induction and was lower in ouabain-treated than in
vehicle-treated PHN rats from the fourth week of observation
(Supplementary Figure S5B). At the end of the follow-up
period, serum creatinine was signiﬁcantly higher in vehicle-
treated than in ouabain-treated PHN rats (Supplementary
Figure S5C).
At time of sacriﬁce, kidneys were prepared for immuno-
histochemistry and morphometric analysis. Analysis of
apoptosis and expression of Bax and Bcl-xL was performed inKidney International (2016) 90, 135–148
Figure 3 | Ouabain protects from albumin-triggered mitochondrial dysfunction. (a) Changes in mitochondrial membrane potential in
RPTCs incubated with vehicle, 2.5 mg/ml albumin, or 2.5 mg/ml albumin and 5nM of ouabain for 8 hours, visualized using JC-1 dye. Aggregation
of JC-1 indicates high-Dj mitochondria in red ﬂuorescence. Monomeric dye indicates low-Dj mitochondria in green ﬂuorescence. Mito-
chondrial depolarization is shown as a decrease in the red-green ﬂuorescence intensity ratio. Bars ¼ 10 mm. (b) Localization of Bax to mito-
chondria in RPTCs incubated with vehicle, 2.5 mg/ml albumin or 2.5 mg/ml albumin and 5 nM of ouabain for 8 hours. Representative confocal
images of Bax immunoﬂuorescence staining shown in red and mitochondria in green, by using the mitochondrial marker BacMam 2.0.
Bars ¼ 5 mm. (c) Bcl-xL expression in RPTCs incubated with vehicle, 2.5 mg/ml albumin, or 2.5 mg/ml albumin and 5 nM of ouabain for 8 hours.
Representative confocal images of Bcl-xL immunoﬂuorescence signal in red and mitochondria in green, by using the mitochondrial marker
BacMam 2.0. Bars ¼ 5 mm. (d) Quantiﬁcation mitochondrial membrane potential change in RPTCs incubated with vehicle (control) or 2.5 mg/ml
albumin in the presence and absence of 5nM ouabain for 8 hours. *P < 0.001. Data are shown as percentage of control, mean  SEM.
Experiments were repeated 3 times. (e) Quantiﬁcation of Bax localization to mitochondria in RPTCs incubated with vehicle (control) or 2.5
mg/ml albumin in the presence and absence of 5 nM ouabain for 8 hours. Colocalization was assessed along 2 perpendicular line traces across
the nucleus. Overlap of mitochondria and Bax ﬂuorescence signal peaks along the lines were analyzed. Peaks were considered to overlap if
spaced by no more than 140 nm. *P < 0.001. Data are shown as percentage of overlapping Bax/mitochondrial peaks, mean  SEM. Experiments
were repeated 4 times. (f) Quantiﬁcation of Bcl-xL expression in RPTCs incubated with vehicle (control) or 2.5 mg/ml albumin in the presence
and absence of 5 nM ouabain for 8 hours. #P < 0.01. All data are shown as percentage of Bcl-xL immune reactivity when control was set to
(Continued)
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=Figure 4 | Long-term treatment with ouabain attenuates apoptosis of renal cortical cells in the PHN rat. (a) Representative
40,6-diamidino-2-phenylindole staining of nuclei in renal cortex of control rats, PHN rats, and ouabain-treated PHN rats at 4 months after PHN
induction. The arrows indicate typical condensed nuclei. For quantiﬁcation, control was set to 100%. Bars ¼ 40 mm. (b) Representative
immunostaining for Bcl-xL in renal cortex of control rats, PHN rats, and ouabain-treated PHN rats at 4 months after PHN induction. For
semiquantitative evaluation of Bcl-xL immunoreactivity signal, control was set to 100%. Bars ¼ 40 mm. (c) Representative immunostaining for
Bax in renal cortex of control rats, PHN rats, and ouabain-treated PHN rats at 4 months after PHN induction. For semiquantitative evaluation
of Bax immunoreactivity signal, control was set to 100%. Bars ¼ 40 mm. For all experiments, analysis was done in 2 sections from each kidney
and in 5 (condensed nuclei) or 6 (Bcl-xL and Bax) randomly selected areas of the outer cortex. Histograms show the mean  SEM. Statistical
analysis was performed using analysis of variance followed by Student t-test. *P < 0.05. Bcl-xL, B-cell lymphoma–extra large; OB, ouabain;
PHN, passive Heymann nephritis.
bas i c re sea r ch I Burlaka et al.: Apoptosis inhibition rescues from albumin toxicitythe outer cortex where the vast majority of tubular cells are
PTCs,49 as seen in Supplementary Figure S6. To assess the
level of apoptosis, we quantiﬁed the number of cells with a
condensed (pyknotic) nucleus, a marker of apoptosis that
correlate well with TUNEL staining (Supplementary
Figure S7). Vehicle-treated PHN animals had a signiﬁcantly
larger number of condensed nuclei than control animals. TheFigure 3 | (Continued) 100%, mean  SEM. Experiments were repeated
control for mitochondrial membrane potential (solid line), localization of
in response to 2.5 mg/ml albumin. (h,i) Quantiﬁcation of mitochondrial m
or 0.2 mg/ml albumin in presence and absence of 5 nM of ouabain for (
mean  SEM. *P < 0.05. #P < 0.05. Experiments were repeated 3 times
whether differences were statistically signiﬁcant. Bcl-xL, B-cell lymphom
140number of condensed nuclei in ouabain-treated PHN animals
was not different from that of control animals (Figure 4a).
Bcl-xL and Bax expression was visualized by immunohisto-
chemistry and semiquantitative evaluation of the ﬂuorescence
signal was performed. Renal cortical expression of Bcl-xL and
Bax was detected in all groups studied (Figure 4b and c). The
Bax immunoﬂuorescence signal was signiﬁcantly higher and4 times. (g) Plot shows time-dependent change as percentage of
Bax to mitochondria (dashed line), and Bcl-xL expression (dotted line)
embrane potential change in RPTCs incubated with vehicle (control)
h) 8 hours and (i) 18 hours. Data are shown as percentage of control,
. For all experiments, Mann-Whitney U test was used to determine
a–extra large; OB, ouabain; RPTCs, rat proximal tubular cells.
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Figure 5 | Kidneys from ouabain-treated PHN rats have fewer disconnected proximal tubules than kidneys from vehicle-treated
PHN rats. (a) Representative terminal deoxynucleotidyltransferase–mediated dUTP nick end-labeling staining of early proximal tubules from
vehicle- and ouabain-treated PHN rats at 4 months after PHN induction. Control rats rarely display any positive terminal deoxynucleotidyl-
transferase–mediated dUTP nick end-labeling stain in this region. Histograms show quantitative determination of apoptotic proximal tubular
cells, shown as mean  SEM. *P < 0.01. (b) Typical periodic acid–Schiff staining of slices for morphometric studies, evaluating the glomerular-
tubular connections in individual glomeruli. Pictures illustrate the pattern of glomerular-tubular connections, each glomerulus in the slide is
counted (left) and evaluated as connected to a normal proximal tubule (middle left), to an atrophic proximal tubule (middle right), or without a
tubular connection, that is, a-tubular glomeruli (right). (c) Summary of morphometric studies. Quantitative determination of glomeruli
connected to an atrophic proximal tubule (left) and a-tubular glomeruli (right). Histograms represent mean  SEM. *P < 0.001; #P < 0.01. For all
experiments, Mann-Whitney U test was used to determine signiﬁcant differences. OB, ouabain; PHN, passive Heymann nephritis.
I Burlaka et al.: Apoptosis inhibition rescues from albumin toxicity ba s i c re sea r chthe Bcl-xL signal was signiﬁcantly lower in sections from
vehicle-treated PHN rats than in sections from control rats. In
contrast, neither the Bax nor the Bcl-xL immunoﬂuorescence
signal was signiﬁcantly different between ouabain-treated
PHN rats and control rats.
Chronic ouabain treatment protects from glomerular-tubular
disconnection in PHN rats
Early PTCs are most exposed to increase in ﬁltered albumin.
The number of apoptotic cells at the level of the glomerular-
tubular junction was 3-fold higher in kidneys from vehicle-
treated than in kidneys from ouabain-treated PHN rats
(Figure 5a). Apoptotic cells in the early PTCs were rarely
observed in control rats (data not shown).Kidney International (2016) 90, 135–148Apoptosis and atrophy of early PTCs may result in
glomerular-tubular disconnection.7 The frequency of existing
and ongoing glomerular-tubular disconnection was studied
with morphometric analysis in each animal using on average
75 serial sections (3–4 mm thickness). The number of
a-tubular glomeruli and atrophic tubuli were assessed as
described by Benigni et al.50 The incidence of a-tubular
glomeruli and glomeruli connected to atrophic tubuli was low
in control rats. We found a large increase in both a-tubular
glomeruli (16%) and glomeruli connected to atrophic tubules
(17%) in vehicle-treated PHN rats. The number of a-tubular
glomeruli and glomeruli connected to atrophic tubules was
signiﬁcantly less pronounced in ouabain-treated PHN rats
(8.5% and 11%, respectively) (Figure 5b and c).141
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142Chronic ouabain treatment protects from loss of podocytes in
PHN rats
Loss of podocytes is generally considered a sign of permanent
renal damage.38,51–54 Kidney sections were stained for the
podocyte marker WT1. The AI of WT1-positive cells was
increased in both vehicle- and ouabain-treated PHN rats, but
the increase was signiﬁcantly less pronounced in ouabain-
treated PHN rats (Figure 6a). There was a large reduction
of WT1-positive cells per glomerulus in vehicle-treated
PHN rats compared with control rats. Signiﬁcantly more
WT1-positive cells were preserved in ouabain-treated PHN
animals (Figure 6b).
Kidney ﬁbrosis and glomerular collagen accumulation is
less pronounced in ouabain-treated than in vehicle-treated
PHN rats
Fibrosis is a typical feature of CKD.14,16 We found up-
regulation of the signal from the proﬁbrotic factor TGF-b1
in vehicle-treated PHN rats compared with control rats. TGF-
b1 up-regulation was not observed in ouabain-treated PHN
rats (Supplementary Figure S8B). Glomerular collagen IV
accumulation was observed in both vehicle- and ouabain-
treated PHN rats, but was more pronounced in vehicle-
treated PHN rats (Supplementary Figure S8C). Kidneys
from adult rats have a regenerative capacity, which may be
preserved in CKD.55,56 Vehicle-treated PHN rats displayed
more proliferating cells, detected by markers Ki-67 and
proliferating cell nuclear antigen (PCNA), than control rats
did. The number of proliferating cells was signiﬁcantly lower
in ouabain-treated than in vehicle-treated PHN rats
(Supplementary Figure S8A).
DISCUSSION
The pathogenesis of CKD is multifactorial. Here we conﬁrm
the observation from many previous studies that apoptosis
contributes to the progressive course of the disease and
demonstrate that the progression can be slowed down by
ouabain, a compound that acts by interfering with the early
phase of the apoptotic process.
There is a great need to develop novel approaches to halt
the progression of CKD and speciﬁcally target the variousFigure 6 | Kidneys from ouabain-treated PHN rats have more
preserved WT1-positive glomerular cells than kidneys from
vehicle-treated PHN rats. (a) Representative micrographs showing
TUNEL stain in WT1-positive glomerular cells from control, vehicle-,
and ouabain-treated PHN rats. Sections were TUNEL-stained (red) to
detect apoptotic cells and stained for WT1 (green) to detect podo-
cytes; DAPI-stained nuclei are shown in blue. Bars ¼ 20 mm. Histo-
gram shows quantiﬁcation of apoptotic podocytes, for control, PHN,
and ouabain-treated PHN rats. Histograms show mean  SEM. (b)
Histogram shows quantiﬁcation of WT1-positive cells per glomerulus
for control, PHN, and ouabain-treated PHN rats. Histograms show
mean  SEM. For all experiments, Mann-Whitney U test was used to
determine signiﬁcant differences. *P < 0.01; #P < 0.05. DAPI, 40,6-
diamidino-2-phenylindole; OB, ouabain; PHN, passive Heymann
nephritis; TUNEL, terminal deoxynucleotidyltransferase–mediated
dUTP nick end-labeling.
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studies have pointed to the importance of apoptosis in CKD,
there is as yet no antiapoptotic drug available. Caspase in-
hibitors have been tested but have failed to reach the mar-
ket.57 Caspase inhibitors interfere with a late stage in the
apoptotic pathway and may therefore prevent death of cells
where DNA damage has already occurred.
To test whether ouabain protects from the early phase of
apoptosis, before the process is irreversible, we focused this
study on the effect of ouabain on 2 important members of
the Bcl family, the apoptotic protein Bax, and the anti-
apoptotic protein Bcl-xL. Bax exists in equilibrium between
cytosolic and mitochondria-associated forms and shifts
toward the latter when activated by a stress stimulus to
induce cell death. Activated Bax accumulates on mito-
chondria and oligomerizes and permeabilizes the mito-
chondrial outer membrane. This results in release of
cytochrome C and marks the point of no return in the
apoptotic process. Bcl-xL prevents Bax recruitment to the
mitochondria and its oligomerization and permeabilization
of the outer mitochondrial membrane. During the course of
the apoptotic process, Bax expression increases and Bcl-xL
expression decreases. Here we demonstrated that ouabain
decreases Bax and increases Bcl-xL expression and that
ouabain prevents mitochondrial Bax accumulation and
depolarization of the outer mitochondrial membrane in
primary PTCs challenged with an excessive load of albumin.
These ﬁndings indicate that ouabain protects against the
onset of albumin-triggered apoptosis. The ouabain effect on
the apoptotic pathway is shown in Supplementary
Figure S9.
The molecular mechanism by which ouabain exerts its
early antiapoptotic effect remains to be elucidated, but it is
likely dependent on a signaling pathway involving calcium
release from the IP3R. It is possible that ouabain can exert
both an acute and a chronic effect. In a previous study,27 we
presented evidence that ouabain may exert a long-term
antiapoptotic effect by activating the nuclear factor kB fac-
tor p65, a transcriptional regulator of Bcl-xL.58 Our obser-
vation that the Bcl-xL abundance is down-regulated in
albumin-triggered cells, maintained in cells treated with
ouabain but not in cells treated with ouabain and helenalin,
an inhibitor of the transcriptional effects of nuclear factor kB,
suggests that this may be the case.
Kidney sections from rats with untreated PHN showed
signs of ongoing proximal tubular apoptosis, as indicated by
increased Bax and decreased Bcl-xL abundance as well as an
elevated number of apoptotic cells. In contrast, a compar-
ison between slices from ouabain-treated PHN rats and
control rats did not reveal signiﬁcant differences with regard
to these parameters. A study of the proximal tubules adja-
cent to the glomeruli showed signiﬁcantly increased num-
ber of apoptotic cells in kidneys from both untreated and
ouabain-treated PHN rats as compared to control rats.
However, the increase was much more pronounced in un-
treated than in treated kidneys from PHN rats. MassiveKidney International (2016) 90, 135–148apoptosis of early PTCs leads to glomerular-tubular
disconnection. Oliver59 ﬁrst described the occurrence of
a-tubular glomeruli in CKD in 1937. A-tubular glomeruli
have more recently been reported in human transplanted
kidneys, kidneys from rats with PHN, and in mouse
models for obstructive kidney disease and polycystic
kidney disease.39,60–62 Yet glomerular-tubular disconnec-
tion has remained an underestimated cause of irreversible
loss of renal function in CKD. Notably, the loss of func-
tional nephrons observed in the untreated PHN rats
correlated well to the increase in serum creatinine
(Supplementary Table S1). Renal tubular cells have a
relatively high regenerative capacity.55,56 The number of
newly formed epithelial cells was increased in kidneys from
both vehicle- and ouabain-treated PHN rats, but the in-
crease was less pronounced in kidneys from ouabain-treated
rats. This regenerative capacity is likely of importance
for the preservation of tubular function, but not sufﬁcient
to repair a well-advanced or complete glomerular-tubular
disconnection.
Excessive exposure to albumin did also trigger apoptosis
in primary rat podocytes. Podocytes have low regenerative
capacity and the importance of podocyte damage for the
progressive course of CKD is well documented. Ouabain
protected from podocyte apoptosis both in vitro and in vivo.
The podocyte AI was higher and there were fewer WT1-
positive cells per glomeruli in kidneys from untreated
than in ouabain-treated PHN rats. PHN is induced by
injection of anti-Fx1A antibody, which mainly targets
podocyte foot processes. We cannot exclude that
complement-dependent cell death may to some extent
contribute to podocytes loss. Cell death due to immune
reaction, however, is mainly mediated via the extrinsic
apoptotic pathway,63,64 which does not involve Bax and Bcl-
xL proteins to the same extent as the mitochondrial
apoptotic pathway. It is therefore unlikely that ouabain
would have interfered with this pathway.
Tubulointerstitial ﬁbrosis is generally considered as the
ﬁnal common pathway of the majority of progressive
CKD.65,66 Apoptosis is regularly observed in ﬁbrotic tissue,
and mounting evidence suggest that apoptosis contributes to
the ﬁbrotic process.31,67–69 It was recently reported that
expression of reticulon 1, a protein that induces apoptosis,
attenuates the ﬁbrotic process and the severity and pro-
gression of CKD in mice and humans.70 In the albumin
exposed PTCs, apoptosis preceded the increase in expression
of the multifunctional protein TGF-b, which triggers for-
mation of extracellular matrix and ﬁbrosis as well as
apoptosis (likely via the extrinsic apoptotic pathway).71
Ouabain down-regulated TGFb expression, both in the
in vitro and in vivo studies, suggesting that execution of
apoptosis via the intrinsic mitochondrial pathway precedes
the increased TGFb expression. Taken together, available
information indicates that a drug targeting the onset of the
mitochondrial apoptotic pathway should be highly beneﬁ-
cial in CKD.143
bas i c re sea r ch I Burlaka et al.: Apoptosis inhibition rescues from albumin toxicityA large number of studies performed on rodents have
suggested that albumin is a major contributor to the pro-
gressive course of CKD. Yet many patients with minimal
change disease or membranous glomerular nephritis can
have stable nephrotic-range proteinuria for many years
without apparent loss of renal function. However, these
observations are not necessarily contradictory. Most patients
with minimal change disease are very young, and it is well
documented that the regenerative capacity of renal tubular
cells is age-dependent and younger patients have a more
favorable prognosis than older patients do.72,73 It is also
important to consider that the progression of CKD to renal
failure is generally a slow process3 that often takes more
than a decade, and most patients are relatively asymptom-
atic as long as 50% of the renal functional capacity is pre-
served. Currently, kidney biopsy specimens from humans
are rarely examined for apoptosis and expression of pro-
apoptotic proteins. More information about the incidence of
apoptosis in human kidneys would likely increase the
awareness that clinically relevant drugs targeting the
apoptotic process before the point of no return would be
beneﬁcial.
In conclusion, this study highlights apoptosis as a cause of
albumin toxicity and as a contributor to the progressive loss
of functional renal tissue in CKD, and it provides a basis for
the development of the cardiotonic steroid ouabain as a
complementary therapy in CKD.MATERIALS AND METHODS
The complete materials and methods including a list of antibodies
used can be found in Supplementary Material.
Animals and rat primary cultures
Forty-day-old male Sprague-Dawley rats were used for the PHN
model. For cell preparation, 20-day-old male Sprague-Dawley rats
were used. All experiments were performed according to Karolinska
Institutet regulations concerning care and use of laboratory animals
and were approved by the Stockholm North Ethical Evaluation
Board for Animal Research.
Primary culture of RPTCs was prepared as previously described.74
Characterization of RPTCs show that on day 3 in culture 99% of the
cells express sodium glucose transport-2 (SGLT-2), a marker for
proximal tubular cells (Supplementary Figure S1A). Glomeruli
isolation and podocytes culture were performed as previously
described.75 Albumin treatment of primary cultures was started on
day 2 or 3 in vitro for all experiments, cells were exposed either
vehicle (phosphate-buffered saline) or fatty acid and endotoxin-free
bovine albumin in the growth media for up to 18 hours, with or
without presence of ouabain 5 nM.
Detection of apoptosis in primary culture
TUNEL assay by use of ApopTag Red In Situ Apoptosis Detection
kit (Merck Millipore, Billerica, MA) was used according to the
manufacturer’s instructions. Nuclei were counterstained with
40,6-diamidino-2-phenylindole (DAPI). For determination of AI in
podocytes, podocytes were detected by anti-WT1 antibody.144Mitochondrial membrane potential determination
The integrity of the mitochondrial membrane potential was
measured in RPTCs using the JC-1 dye (Life Technologies,
Thermo Fisher Scientiﬁc, Carlsbad, CA). Mitochondrial depo-
larization is detected by a shift in ﬂuorescence emission from red
(w590 nm) to green (w527 nm). Cells were incubated with
2.5 mg/ml JC-1 dye in cultured medium for 15 minutes at 37 C
and then analyzed. The mitochondrial membrane potential
change was quantiﬁed by calculating the ratio of red to green
ﬂuorescence intensity.
Immunocytochemistry
RPTCs and podocytes in primary culture were ﬁxed in 4% para-
formaldehyde for 10 minutes, washed and treated with 0.3% Triton
X-100 for 10 minutes. Then incubated with 5% bovine serum al-
bumin, 0.1% Triton X-100, for 1 hour. Primary antibodies were
applied overnight at 4 C. Following 3 washes, cells were incubated
with secondary antibodies for 1 hour at room temperature. Cells
were washed and mounted for analysis.
Bax, Bcl-xL translocation assessment
RPTCs on day 2 in vitro were labeled with CellLight Mitochondria-
GFP BacMam (Life Technologies) overnight. The following day,
RPTCs were incubated with albumin with or without ouabain or
vehicle for up to 8 hours. Following incubation, cells were immu-
nostained for Bax or Bcl-xL, and analysis of Bax/Bcl-xL translocation
to the mitochondria was done. To assess colocalization between
immune-labeled Bax/Bcl-xL and green ﬂuorescent protein–express-
ing mitochondria, the method of Edlich et al. (2011)23 was used.
Results are shown as fraction of Bax/Bcl-xL—mitochondria overlap
to total number of mitochondria.
Animal model, passive Heymann nephritis
Animals were divided into a control group and a PHN group. PHN
was induced by a single injection of rabbit anti-Fx1A antibody
(a kind gift from Professor David J. Salant, Boston University
Medical Center), control rats were given vehicle. On day 0 after PHN
injection, one-half of the group was started on ouabain treatment
(15 mg/ml/day) and the other half was given vehicle (sterile
phosphate-buffered saline) delivered by minipumps implanted
subcutaneously. All animals were followed for 4 months. Spot urine
samples were collected every second week and albuminuria was
measured using Nephrat II (Exocell, Philadelphia, PA). At killing,
blood samples were collected for serum creatinine determination
and kidneys were removed from for histological and morphological
studies.
Renal histology and morphometric analysis
Dissected kidneys were ﬁxed in Dubosq-Brazil, dehydrated in
alcohol, and embedded in parafﬁn. Kidney sections 3 to 4 mm were
stained with periodic acid–Schiff reagent, and sections including
superﬁcial and juxtamedullary glomeruli were evaluated.
To assess glomerular-tubular disconnection, on average, 75 serial
sections (3–4 mm) were examined for each animal. For each group of
animals, 300 to 320 glomeruli were examined. Only glomeruli
located entirely within the serially sectioned tissue were included in
the analysis. The glomeruli were classiﬁed as connected to a normal
proximal tubule, connected to an atrophic proximal tubule, or
without a tubular connection.Kidney International (2016) 90, 135–148
I Burlaka et al.: Apoptosis inhibition rescues from albumin toxicity ba s i c re sea r chDetection of apoptosis in renal tissue
To detect apoptotic PTCs, kidney sections were deparafﬁnized,
rehydrated, and subjected to antigen retrieval, and nuclei were
stained with DAPI and sections mounted with Immu-Mount
(Thermo Fisher Scientiﬁc, Kalamazoo, MI). All samples were
stained under identical conditions and analyzed using identical mi-
croscopy settings. Cells were classiﬁed as being apoptotic if they had
a condensed nucleus, where the nuclei was shrunken and had
abnormal morphology with no visible interior.
To detect apoptotic podocytes, sections were consecutively
immunostained using WT1 antibodies, a podocyte marker, followed
by ApopTag Red In Situ Apoptosis Detection kit according to the
manufacturer’s instructions.
To evaluate apoptotic PTCs at the level of the glomerular-tubular
junction, sections were stained with Peroxidase In Situ Apoptosis
Detection kit (Merck Millipore) according to manufacturer’s in-
structions and counterstained with Harris hematoxylin (Richard
Allan Scientiﬁc, Thermo Fisher Scientiﬁc). Sections were assessed
and the number of apoptotic cells per glomerular-tubular junction
was determined. In each slice, 25 to 30 randomly selected glomeruli
were examined.
Statistical analysis
Results are presented as mean  SEM. To determine differences
among groups, 2-way analysis of variance followed by Fisher-LSD
post hoc test was used. If the distribution of the variables was not
parametric, the nonparametric Mann-Whitney test was used.
Comparisons between groups were made using Kruskal-Wallis 1-way
analysis of variance on ranks with pair-wise multiple comparisons
made by Dunn method.
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SUPPLEMENTARY MATERIAL
Supplementary Materials and Methods
Figure S1. Rat proximal tubule cells in culture: maintenance of
fenotype, TGF-b1 response to albumin uptake, and lack of
ouabain effect on albumin uptake. (A) Characterization of RPTCs.
RPTCs on day 3, 6, and 10 in culture were immunostained for SGLT-2
(green), a marker of proximal tubule cells, and for alpha-smooth
muscle actin (red), a marker of ﬁbroblasts, and DAPI (blue) to count
the total number of cells. At day 3, 99% of the cells express SGLT-2
and 1% expressed alpha-smooth muscle actin. At day 6, 75% and at
day 10, 46% of the cells were SGLT-2–positive and alpha-smooth
muscle actin–negative. In addition, at day 6, 25% and at day 10, 53%
express both SGLT-2 and alpha-smooth muscle actin. (B) TGF-b1
expression detected by immunoblotting in RPTCs incubated with or
without 10 mg/ml albumin and in combination with ouabain 5 nM
for 8 or 18 hours. Histograms show quantiﬁcation of albumin-Kidney International (2016) 90, 135–148induced TGF-b1 expression data are mean  SEM. **P < 0.001; *P <
0.01. Experiments were repeated 4 times. (C) Ouabain does not in-
ﬂuence RPTCs albumin uptake. RPTCs incubated with 2.5 mg/ml
albumin and 10 ml/ml Alexa 555 albumin with or without 5 nM
ouabain for 2 hours. Histograms show quantiﬁcation of Alexa 555
albumin signal per cell. Data are shown as mean  SEM. Experi-
ments were repeated 6 times. DAPI, 40,6-diamidino-2-phenylindole;
RPTCs, rat proximal tubular cells; SGLT-2, sodium glucose
transporter-2; TGF, transforming growth factor.
Figure S2. Ouabain does not inhibit LPS stimulated cytokine
expression. Quantiﬁcation of expression of the inﬂammatory
cytokines, IL-1b (top) and IL-6 (bottom), after incubation with
LPS 1mg/ml for 0, 1, 2, 4, or 8 hours, and for 8 hours together
with 5 nM ouabain. Experiments were repeated 3 times. Data are
mean  SEM, **P < 0.001; *P<0.01. IL, interleukin; LPS,
lipopolysaccharide.
Figure S3. Time-dependent effects of early apoptotic signs
triggered by 10 mg/ml albumin exposure. (A) Quantiﬁcation of Bcl-
xL localization to mitochondria in RPTCs incubated with 2.5 mg/ml
(open bars) and 10 mg/ml (gray bars) albumin for 8 hours in presence
and absence of 5 nM ouabain. All data are shown as percentage of
overlapping Bcl-xl/mitochondrial peaks, mean  SEM. Experiments
were repeated 4 times. (B) Plot shows time-dependent change as
percentage of control for mitochondrial membrane potential (solid
line), localization of Bax to mitochondria (broken line), and Bcl-xL
expression (dotted line) in RPTCs exposed to 10 mg/ml albumin. (C)
Quantiﬁcation of mitochondrial membrane potential change in RPTCs
incubated with vehicle (control) or 10 mg/ml albumin in presence
and absence of 5nM of ouabain for 8 hours. *P < 0.001; #P < 0.01.
Data are shown as percentage of control, mean  SEM. Experiments
were repeated 3 times. (D) Quantiﬁcation of Bax localization to
mitochondria in RPTCs incubated with vehicle (control) or 10 mg/ml
albumin in presence and absence of 5 nM of ouabain for 8 hours.
*P < 0.001; #P < 0.01. Data are shown as percentage of overlapping
Bax/mitochondrial peaks, mean  SEM. Experiments were repeated
4 times. (E) Quantiﬁcation of Bcl-xL expression in RPTCs incubated
with vehicle (control) or 10 mg/ml albumin in presence and
absence of 5 nM of ouabain for 8 hours. *P < 0.001; #P < 0.01.
Data are shown as percentage of Bcl-xL immune reactivity when
control was set to 100%, mean  SEM. Experiments were repeated
4 times. Bcl-xL, B-cell lymphoma–extra large; OB, ouabain; RPTCs, rat
proximal tubular cells.
Figure S4. Initial effects of 10 mg/ml albumin exposure of
proximal tubular cells on Bax expression and mitochondrial
membrane potential. (A) Albumin uptake, RPTCs were incubated
with 10 mg/ml albumin and trace Alexa 555 coupled albumin for 5,
15, 30, and 45 minutes. All images represent a single section through
the focal plane. (B) Localization of Bax to mitochondria in RPTCs
incubated with 10 mg/ml albumin for 5, 15, 30, and 45 minutes. Bax
immunoﬂuorescence staining is shown in red and mitochondria in
green, by using the mitochondrial marker BacMam 2.0. Histograms
show percentage of overlapping Bax/mitochondrial peaks, mean 
SEM. Experiments were repeated 3 times. *P < 0.05 and **P < 0.01
versus control rats. (C) Mitochondrial membrane potential change in
RPTCs incubated with albumin 10 mg/ml for 5, 15, 30, and 45
minutes. Mitochondrial membrane potential change was visualized
using JC-1 dye; green shows depolarized membrane, red shows
polarized membrane. Histograms show percentage of control, mean
 SEM. Experiments were repeated 3 times. **P < 0.01 versus control.
RPTCs, rat proximal tubular cells.
Figure S5. Blood pressure, albumin excretion, and serum
creatinine in vehicle- and ouabain-treated control and PHN rats.
(A) Heart rate in mm Hg (left) and blood pressure in bpm (right) for
vehicle- and ouabain- treated (15 mg/kg/day) rats during 8 weeks.145
bas i c re sea r ch I Burlaka et al.: Apoptosis inhibition rescues from albumin toxicityMeasurements were performed on unanesthetized rats using tail cuff.
Data are mean  SEM. (B) Urinary albumin/creatinine levels in
control, vehicle-, and ouabain-treated (15 mg/kg/day) PHN rats during
16 weeks. Data are mean  SEM. *P< 0.05 for control versus PHN and
control versus PHN þ ouabain at 2 weeks. #P < 0.05 for control versus
PHN, control versus PHN þ ouabain, and PHN versus PHN þ ouabain
at the corresponding time points. For all experiments, statistical
analysis was performed using 2-way analysis of variance. (C) Serum
creatinine levels (mg/dl) in control, vehicle-, and ouabain-treated
(15 mg/kg/day) PHN rats at experiment end point at 16 weeks. His-
tograms show the mean  SEM. The Mann-Whitney U test was
used to determine whether differences were statistically signiﬁcant.
**P < 0.001; *P < 0.01. bpm, beats per minute; OB, ouabain; PHN,
passive Heymann nephritis.
Figure S6. Identiﬁcation of proximal tubular cells in kidney
sections. Analysis of apoptosis by condensed nuclei, expression of
Bax and Bcl-xL done in control, PHN, and ouabain-treated PHN rats as
presented in Figure 4 was performed exclusively in the outer cortical
layer. The majority of tubules in the cortical area (left image) are
proximal tubules as veriﬁed by immunostaining for SGLT-2 (green)
used as a speciﬁc marker of proximal tubule cells. In comparison, an
area closer to the center of the kidney slice has few or no proximal
tubules as shown by the absence of SGLT-2 staining (right image).
DAPI staining of nuclei is shown in blue. Bars ¼ 40 mm. DAPI, 40,6-
diamidino-2-phenylindole; PHN, passive Heymann nephritis; SGLT-2,
sodium glucose transporter-2.
Figure S7. Comparison of condensed nuclei and TUNEL methods
for assessment of apoptosis. RPTCs on the same coverslip were
analyzed using both condensed nuclei and TUNEL. Studies were
performed on control RPTCs and RPTCs exposed to 2.5 to 10 mg/ml
albumin for 8 hours. The plot (left) shows the percentage of apoptosis
expressed by condensed nuclei and by TUNEL for each coverslip
analyzed. There is a linear correlation between the 2 methods,
y ¼ 0.9944x and R2 ¼ 0.7339. The table (right) shows the average
percentage of apoptosis for each treatment assessed with condensed
nuclei and with TUNEL. RPTCs, rat proximal tubular cells; TUNEL,
terminal deoxynucleotidyltransferase–mediated dUTP nick end-
labeling.
Figure S8. Cell proliferation, TGF-b1 expression, and glomerular
collagen in kidney sections from PHN rats. (A) Quantiﬁcation of
proliferative markers Ki-67 and PCNA from immunohistochemistry in
kidney sections from control, PHN, and ouabain-treated PHN rats.
Histograms show mean  SEM. Mann-Whitney U test was used to
determine signiﬁcant differences. **P < 0.001. (B) Representative
expression of proﬁbrotic factor TGF-b1 (red) and nuclei (DAPI, blue)
in control, vehicle-treated PHN, and ouabain-treated PHN rats.
Semiquantitative evaluation of the TGF-b1 signal was performed
in section from control, vehicle-treated PHN, and ouabain-treated
PHN animals, and 3 areas corresponding to 75% of the cortex
were analyzed. Immunoreactivity for TGF-b1 is expressed as per-
centage of deviation from control. Histograms show mean  SEM.
Statistical analysis was performed using the Mann-Whitney U test.
**P < 0.001. (C) Representative images of collage IV immunostaining
in glomeruli of control, vehicle-treated, and ouabain-treated PHN
rats. The images are representative. Level of collagen IV in control
animals was set to baseline and data are expressed as percentage
increase from control. Histograms show mean  SEM. Statistical
analysis was performed using the Mann-Whitney U test. *P < 0.05
DAPI, 40,6-diamidino-2-phenylindole; PCNA, proliferating cell nuclear
antigen; PHN, passive Heymann nephritis; TGF, transforming growth
factor.
Figure S9. Ouabain rescues from albumin-triggered apoptosis
before the point of no return. The intrinsic mitochondrial apoptotic146program is controlled by the Bcl-2 family of apoptotic and
antiapoptotic proteins. Bcl-xL is a prominent member of the
antiapoptotic Bcl-2 proteins, and Bax is a prominent member of
the apoptotic Bcl-2 proteins. Under control conditions, Bax is mainly
located in the cytosol and Bcl-xL on the mitochondria. Apoptosis is
initiated by the restructuring of Bax and its translocation to the
mitochondria. Bcl-xL acts by retranslocating Bax to the cytosol.
Accumulation of Bax on the mitochondria promotes its homo-
oligomerization as well as its hetero-oligomerization with other
apoptotic proteins.24,76 This results in permeabilization of the mito-
chondrial membrane and leakage of cytochrome C, which marks the
point of no return in the apoptotic process. During the course of the
apoptotic process, the abundance of Bax increases and the abun-
dance of Bcl-xL decreases. Ouabain acts by protecting from the
accumulation of Bax on the mitochondrial membrane as well as from
up-regulation of Bax and down-regulation of Bcl-xL abundance.
Bcl-xL, B-cell lymphoma–extra large.
Table S1. Correlation between atrophic/loss of glomerular tubular
junction and serum creatinine in control and PHN rats. OB, ouabain;
PHN, passive Heymann nephritis.
Supplementary material is linked to the online version of the paper at
www.kidney-international.org.
REFERENCES
1. United States Renal Data System. USRDS 2013 Annual Data Report: Atlas
of Chronic Kidney Disease and End-Stage Renal Disease in the United
States. Bethesda, MD: National Institutes of Health, National Institute of
Diabetes and Digestive and Kidney Diseases; 2013.
2. Anderson S, Halter JB, Hazzard WR, et al, for the High KP, Workshop
Participants. Prediction, progression, and outcomes of chronic kidney
disease in older adults. J Am Soc Nephrol. 2009;20:1199–1209.
3. Inker LA, Lambers Heerspink HJ, Mondal H, et al. GFR decline as an
alternative end point to kidney failure in clinical trials: a meta-analysis of
treatment effects from 37 randomized trials. Am J Kidney Dis. 2014;64:
848–859.
4. Haraldsson B, Nyström J, Deen WM. Properties of the glomerular barrier
and mechanisms of proteinuria. Physiol Rev. 2008;88:451–487.
5. Remuzzi G, Perico N, Macia M, Ruggenenti P. The role of renin-
angiotensin-aldosterone system in the progression of chronic kidney
disease. Kidney Int Suppl. 2005;99:S57–65.
6. Chevalier RL, Forbes MS. Generation and evolution of atubular
glomeruli in the progression of renal disorders. J Am Soc Nephrol.
2008;19:197–206.
7. Lindop GB, Gibson IW, Downie TT, et al. The glomerulo-tubular junction:
a target in renal diseases. J Pathol. 2002;197:1–3.
8. Fukuda A, Wickman LT, Venkatareddy M, et al. Progression is caused by
angiotensin II-dependent persistent podocytes loss from destabilized
glomeruli. Kidney Int. 2012;81:40–55.
9. Weening JJ, Ronco P, Remuzzi G. Advances in the pathology of
glomerular diseases. Contrib Nephrol. 2013;181:12–21.
10. Tojo A, Kinugasa S. Mechanisms of glomerular albumin ﬁltration and
tubular reabsorption. Int J Nephrol. 2012;2012:481520.
11. Perkins BA, Ficociello LH, Ostrander BE, et al. Microalbuminuria and the
risk for early progressive renal function decline in type 1 diabetes. J Am
Soc Nephrol. 2007;18:1353–1361.
12. Zoja C, Abbate M, Remuzzi G. Progression of renal injury toward
interstitial inﬂammation and glomerular sclerosis is dependent
on abnormal protein ﬁltration. Nephrol Dial Transplant. 2015;30:
706–712.
13. Birn H, Christensen EI. Renal albumin absorption in physiology. Kidney
Int. 2006;69:440–449.
14. Brezniceanu M-L, Liu F, Wei C-C, et al. Attenuation of interstitial ﬁbrosis
and tubular apoptosis in db/db transgenic mice overexpressing catalase
in renal proximal tubular cells. Diabetes. 2008;57:451–459.
15. Sanz AB, Santamaría B, Ruiz-Ortega M, et al. Mechanisms of renal
apoptosis in health and disease. J Am Soc Nephrol. 2008;19:
1634–1642.
16. Eddy AA. Molecular basis of renal ﬁbrosis. Pediatr Nephrol. 2000;15:
290–301.Kidney International (2016) 90, 135–148
I Burlaka et al.: Apoptosis inhibition rescues from albumin toxicity ba s i c re sea r ch17. Erkan E, Devarajan P, Schwartz GJ. Mitochondria are the major targets in
albumin-induced apoptosis in proximal tubule cells. J Am Soc Nephrol.
2007;18:1199–1208.
18. Erkan E, Garcia CD, Patterson LT, et al. Induction of renal tubular cell
apoptosis in focal segmental glomerulosclerosis: roles of proteinuria and
Fas-dependent pathways. J Am Soc Nephrol. 2005;16:398–407.
19. Jafar TH, Stark PC, Schmid CH, et al, for the AIPRD Study Group. The
effect of angiotensin-converting-enzyme inhibitors on progression of
advanced polycystic kidney disease. Kidney Int. 2005;67:265–271.
20. Essien E, Goel N, Melamed ML. Role of vitamin D receptor activation in
racial disparities in kidney disease outcomes. Semin Nephrol. 2013;33:
416–424.
21. Akhurst RJ, Hata A. Targeting the TGFb signaling pathway in disease. Nat
Rev Drug Discov. 2012;11:790–811.
22. de Zeeuw D, Agarwal R, Amdahl M, et al. Selective vitamin D receptor
activation with paricalcitol for reduction of albuminuria in patients with
type 2 diabetes (VITAL study): a randomised controlled trial. Lancet.
2010;376:1543–1551.
23. Edlich F, Banerjee S, Suzuki M, et al. Bcl-x(L) retrotranslocates Bax from
the mitochondria into the cytosol. Cell. 2011;145:104–116.
24. Chen HC, Kanai M, Inoue-Yamauchi A, et al. An interconnected
hierarchical model of cell death regulation by the BCL-2 family. Nat Cell
Biol. 2015;17:1270–1281.
25. Miyakawa-Naito A, Uhlen P, Lal M, et al. Cell signaling microdomain with
Na,K-ATPase and inositol 1,4,5-trisphosphate receptor generates calcium
oscillations. J Biol Chem. 2003;278:50355–50361.
26. Aizman O, Uhlen P, Lal M, et al. Ouabain, a steroid hormone that
signals with slow calcium oscillations. Proc Natl Acad Sci U S A. 2001;98:
13420–13424.
27. Li J, Zelenin S, AperiaA, AizmanO. Lowdosesof ouabain protect fromserum
deprivation–triggered apoptosis and stimulate kidney cell proliferation via
activation of NF-kappaB. J Am Soc Nephrol. 2006;17:1848–1857.
28. Fontana JM, Burlaka I, Khodus G, et al. Calcium oscillations triggered by
cardiotonic steroids. FEBS J. 2013;280:5450–5455.
29. Aperia A. 2011 Homer Smith Award: to serve and protect: classic and
novel roles for Naþ, Kþ-adenosine triphosphatase. J Am Soc Nephrol.
2012;23:1283–1290.
30. Burlaka I, Liu XL, Rebetz J, et al. Ouabain protects from Shiga toxin-
triggered apoptosis by reversing the imbalance between Bax and Bcl-xL.
J Am Soc Nephrol. 2013;24:1413–1423.
31. Aperia AC, Akkuratov EE, Fontana JM, Brismar H. Naþ, Kþ-ATPase, a new
class of plasma membrane receptors. Am J Physiol Cell Physiol. 2016;310:
C491–495.
32. Dvela-Levitt M, Cohen-Ben Ami H, Rosen H, et al. Reduction in maternal
circulating ouabain impair offspring growth and kidney development.
J Am Soc Nephrol. 2015;26:1103–1114.
33. Jacobs BE, Liu Y, Pulina MV, et al. Normal pregnancy: mechanisms
underlying the paradox of a ouabain-resistant state with elevated
endogenous ouabain, suppressed arterial sodium calcium exchange,
and low blood pressure. Am J Physiol Heart Circ Physiol. 2012;302:
H1317–1329.
34. Li J, Khodus GR, Kruusmägi M, et al. Ouabain protects against adverse
developmental programming of the kidney. Nat Commun. 2010;1:42.
35. Pasdois P, Quinlan CL, Rissa A, et al. Ouabain protects rat hearts against
ischemia-reperfusion injury via pathway involving src kinase, mitoKATP,
and ROS. Am J Physiol Heart Circ Physiol. 2007;292:H1470–1478.
36. Dvela-Levitt M, Ami HC, Rosen H, et al. Ouabain improves functional
recovery following traumatic brain injury. J Neurotrauma. 2014;31:
1942–1947.
37. Peired A, Angelotti ML, Ronconi E, et al. Proteinuria impairs podocytes
regeneration by sequestering retinoic acid. J Am Soc Nephrol. 2013;24:
1756–1768.
38. Mundel P, Reiser J. Proteinuria: an enzymatic disease of the podocyte?
Kidney Int. 2010;77:571–580.
39. Jefferson JA, Pippin JW, Shankland SJ. Experimental models of
membranous nephropathy. Drug Discov Today Dis Models. 2010;7:27–33.
40. Cybulsky AV, Quigg RJ, Salant DJ. Experimental membranous
nephropathy redux. Am J Physiol Renal Physiol. 2005;289:F660–671.
41. Amsellem S, Gburek J, Hamard G, et al. Cubulin is essential for albumin
reabsorption in the renal proximal tubule. J Am Soc Nephrol. 2010;21:
1859–1867.
42. Khan S, Abu Jawdeh BG, Goel M, et al. Lipotoxic disruption of NHE1
interaction with PI(4,5)P2 expedites proximal tubule apoptosis. J Clin
Invest. 2014;124:1057–1068.Kidney International (2016) 90, 135–14843. Lau GJ, Godin N, Maachi H, et al. Bcl-2-modifying factor induces renal
proximal tubular cell apoptosis in diabetic mice. Diabetes. 2012;61:
474–484.
44. Dizin E, Hasler U, Nlandu-Khodo S, et al. Albuminuria induces a
proinﬂammatory and proﬁbrotic response in cortical collecting ducts via
the 24p3 receptor. Am J Physiol Renal Physiol. 2013;305:1053–1063.
45. Galluzzi L, Aaronson SA, Abrams J, et al. Guidelines for the use and
interpretation of assays for monitoring cell death in higher eukaryotes.
Cell Death Differ. 2009;16:1093–1107.
46. Su J, Li SH, Chen ZH, et al. Evaluation of podocytes lesion in patients with
diabetic nephropathy: Wilms’ tumor-1 protein used as a podocyte
marker. Diabetes Res Clin Pract. 2010;87:167–175.
47. Zhang S, Malmersjo S, Li J, et al. Distinct role of the N-terminal tail of the
Na,K-ATPase catalytic subunit as a signal transducer. J Biol Chem.
2006;281:21954–21962.
48. Oken DE, Flamenbaum W. Micropuncture studies of proximal tubule
albumin concentrations in normal and nephrotic cells. J Clin Invest.
1971;50:1498–1505.
49. Larsson SH, Larsson L, Lechene C, Aperia A. Studies of terminal
differentiation of electrolyte transport in the renal proximal tubule using
short-term primary cultures. Pediatr Nephrol. 1989;3:363–368.
50. Benigni A, Gagliardini E, Remuzzi A, et al. Angiotensin-converting
enzyme inhibition prevents glomerular-tubule disconnection and
atrophy in passive Heymann nephritis, an effect not observed with a
calcium antagonist. Am J Pathol. 2001;159:1743–1750.
51. Chang AM, Ohse T, Krofft RD, et al. Albumin-induced apoptosis of
glomerular parietal epithelial cells is modulated by extracellular
signal-regulated kinase 1/2. Nephrol Dial Transplant. 2012;27:
1330–1343.
52. Okamura K, Dummer P, Kopp J, et al. Endocytosis of albumin by
podocytes elicits an inﬂammatory response and induces apoptotic cell
death. PLoS One. 2013;8:e54817.
53. Matsusaka T, Kobayashi K, Kon V, et al. Glomerular sclerosis is prevented
during urinary tract obstruction due to podocyte protection. Am J Physiol
Renal Physiol. 2011;300:F792–F800.
54. Wiggins RC. The spectrum of podocytopathies: a unifying view of
glomerular diseases. Kidney Int. 2007;71:1205–1214.
55. Kale S, Karihaloo A, Clark P, et al. Bone marrow stem cells contribute to
repair of the ischemically injured renal tubule. J Clin Invest. 2003;112:
42–49.
56. Dufﬁeld JS, Park KM, Hsiao LL, et al. Restoration of tubular epithelial cells
during repair of the postischemic kidney occurs independently of bone
marrow-derived stem cells. J Clin Invest. 2005;115:1743–1755.
57. MacKenzie SH, Schipper JL, Clark AC. The potential for caspases in drug
discovery. Curr Opin Drug Discov Devel. 2010;13:568–576.
58. del Nogal M, Luengo A, Olmos G, et al. Balance between apoptosis or
survival induced by changes in extracellular matrix composition in
human mesangial cells: a key role for ILK-NFkB pathway. Apoptosis.
2012;17:1261–1274.
59. Oliver J. The aglomerular nephrons of terminal Bright’s disease. In:
Oliver J, ed. Architecture of the Kidney in Chronic Bright’s Disease. New
York, NY: Paul B. Hoeber; 1937:43–57.
60. Gibson IW, Downie TT, More IAR, Lindop GB. Atubuli glomeruli and
glomerular cysts–a possible pathway for nephron loss in the human
kidney? J Pathol. 1996;179:421–426.
61. Forbes MS, Thornhill BA, Galarreta CI, et al. Chronic unilateral obstruction
in the neonatal mouse delays maturation of both kidneys and leads to
late formation of atubular glomeruli. Am J Physiol Renal Physiol. 2013;305:
F1736–F1764.
62. Galarreta CI, Grantham JJ, Forbes MS, et al. Tubular obstruction leads
to progressive proximal tubular injury and atubular injury and
atubular glomeruli in polycystic kidney disease. Am J Pathol. 2014;184:
1957–1966.
63. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone
deacetylase inhibitors. Nat Rev Drug Discov. 2006;5:769–784.
64. Czaja AJ. Targeting apoptosis in autoimmune hepatitis. Dig Dis Sci.
2014;59:2890–2904.
65. Eddy AA. The origin of scar-forming kidney myoﬁbroblasts. Nat Med.
2013;19:964–966.
66. Papasotiriou M, Genovese F, Klinkhammer BM, et al. Serum and urine
markers of collagen degradation reﬂect renal ﬁbrosis in experimental
kidney diseases. Nephrol Dial Transplant. 2015;30:1112–1121.
67. Johnson A, Di Pietro LA. Apoptosis and angiogenesis: an evolving
mechanism for ﬁbrosis. FASEB J. 2013;27:3893–3901.147
bas i c re sea r ch I Burlaka et al.: Apoptosis inhibition rescues from albumin toxicity68. Wang K, Lin B, Brems JJ, Garnelli RL. Hepatic apoptosis can modulate
liver ﬁbrosis through TIMP1 pathway. Apoptosis. 2013;18:566–577.
69. Spender LC, Carter MJ, O’Brien DI, et al. Transforming growth factor-b
directly induces p53-upregulated modulator of apoptosis (PUMA) during
the rapid induction of apoptosis in Myc-driven B-cell lymphomas. J Biol
Chem. 2013;288:5198–5209.
70. Fan Y, Xiao W, Li Z, et al. RTN1 mediates progression of kidney disease by
inducing ER stress. Nat Commun. 2015;6:7841.
71. Gentle ME, Shi S, Daehn I, et al. Epithelial cell TGFb signaling induces
acute tubular injury and interstitial inﬂammation. J Am Soc Nephrol.
2013;24:787–799.
72. Celsi G, Jakobsson B, Aperia A. Inﬂuence of age on compensatory renal
growth in rats. Pediatr Res. 1986;20:347–350.14873. Mendonҫa AC, Oliveira EA, Fróes BP, et al. A predictive model of
progressive chronic kidney disease in idiopathic nephrotic syndrome.
Pediatr Nephrol. 2015;30:2011–2020.
74. Khan F, Spicarová Z, Zelenin S, et al. Negative reciprocity between
angiotensin II type 1 and dopamine D1 receptors in rat renal
proximal tubule cells. Am J Physiol Renal Physiol. 2008;295:
F1110–F1116.
75. Lal MA, Andersson AC, Katayama K, et al. Rhophilin-1 is a key regulator of
the podocytes cytoskeleton and is essential for glomerular ﬁltration.
J Am Soc Nephrol. 2015;26:647–662.
76. Große L, Wurm CA, Brüser C, et al. Bax assembles into large ring-like
structures remodeling the mitochondrial outer membrane in apoptosis.
EMBO J. 2016;35:402–413.Kidney International (2016) 90, 135–148
